SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKRO

20d ago, source:

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ:AKRO). Such investors are ...

6 Stocks Positioned to Soar as Investors Focus on MASH

4d ago, source:

Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades.

Hepion ends Phase 2 study for NASH drug due to cash restraints

on MSN ago, source:

Hepion Pharmaceuticals (HEPA) has decided to wind down its ASCEND-NASH Phase 2 study due to cash constraints as it explores ...

Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time

13d ago, source: Seeking Alpha

The combined company will operate under the name “Gyre Therapeutics, Inc.” (“Gyre”). As a result of the business combination, ...